Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Emily Rozsahegyi"'
Autor:
Oleg Schmidt-Kittler, Michael Sheets, Yoon-Koo Kang, Chandrasekhar V. Miduturu, Richard D. Kim, Andy Boral, Joseph L. Kim, Nooreen Rubin, Neil Bifulco, Emily Rozsahegyi, Cori Ann Sherwin, Megan A. Hatlen, Natasja Brooijmans, Marion Dorsch, Hongliang Shi, Beni B. Wolf, Klaus P. Hoeflich, Christoph Lengauer, Timothy J. Guzi
Publikováno v:
Cancer Discovery. 9:1686-1695
Hepatocellular carcinoma (HCC) is a leading cause of cancer mortality worldwide with no clinically confirmed oncogenic driver. Although preclinical studies implicate the FGF19 receptor FGFR4 in hepatocarcinogenesis, the dependence of human cancer on
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::cfb336958095dcb0a493f3604a752c01
https://doi.org/10.1158/2159-8290.cd-19-0367
https://doi.org/10.1158/2159-8290.cd-19-0367
Autor:
Emily Rozsahegyi, Ruduan Wang, Riadh Lobbardi, Grace O. Silva, Joseph L. Kim, Dean Zhang, Victoria Tzortziou Brown, Jian Guo, Richard Vargas, Megan A. Hatlen, Marion Dorsch, Doug Wilson, Yoon Jin Choi, Rich Woessner, Phil Ramsden, Neil Bifulco, Michelle Maynard, Faith Stevison, Emanuele Perola, Rob Meissner, Klaus P. Hoeflich, Yeon Seo Choi, Tim LaBranche, Steve Wenglowsky
Publikováno v:
Cancer Research. 81:1279-1279
Background: Cyclin dependent kinases (CDK) comprise a family of proteins which are activated upon cyclin binding to promote cell cycle progression. Historically, CDK family inhibitors have had limited utility in the clinic due to 1) toxicities associ
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a09f8cd954d28465a9103a79c7a17d6d
https://doi.org/10.1158/1538-7445.am2021-1279
https://doi.org/10.1158/1538-7445.am2021-1279
Autor:
Beni B. Wolf, Cori-Ann Sherwin, Natasja Brooijmans, Christoph Lengauer, Hongliang Shi, Megan A. Hatlen, Michael Sheets, Neil Bifulco, Emily Rozsahegyi, Chandra Miduturu, Yoon-Koo Kang, Marion Dorsch, Richard D. Kim, Nooreen Rubin, Klaus P. Hoeflich, Oleg Schmidt-Kittler, Andy Boral, Joseph L. Kim, Timothy J. Guzi
Publikováno v:
Molecular Cancer Therapeutics. 18:A118-A118
When on-target resistance mutations occur in response to potent and selective therapeutics, the target is often considered a validated driver of disease. Hepatocellular carcinoma (HCC) is a leading cause of cancer mortality worldwide whose drivers re
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::705d66d87fd0d1bda277b4d4b0bd2564
https://doi.org/10.1158/1535-7163.targ-19-a118
https://doi.org/10.1158/1535-7163.targ-19-a118